Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Guardant Health (GH) Stock Price & Analysis
1,710 Followers
GH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.81 - $41.06
Previous Close$24.77
Volume394.22K
Average Volume (3M)2.22M
Market Cap
$2.99B
Enterprise Value$4.35B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)-6.3
Beta1.79
Next Earnings
Aug 01, 2024EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding122,369,214
10 Day Avg. Volume3,108,616
30 Day Avg. Volume2,216,769
Standard Deviation0.15
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)54.73
Price to Sales (P/S)17.99
Price to Cash Flow (P/CF)-25.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.21
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda-8.25
Forecast
1Y Price Target
$36.33Price Target Upside48.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Guardant Health News
PremiumEarning Releases
Guardant Health Earnings Report: Is it a Beat?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGuardant Health's impressive financial results, with a strong quarter surpassing revenue expectations and a raised outlook for the year, signal a robust financial trajectory that could uplift investor sentiment.
Market PositionAnalyst confidence in Guardant Health is reinforced by the company's leading role in the liquid biopsy market and its strategic moves to secure CMS reimbursement and ADLT listing, paving the way for sustained growth.
Regulatory MilestonesThe upcoming AdCom meeting for Guardant Health's Shield IVD could be a pivotal moment, with the potential to significantly boost the stock as it may lead to expanded use and increased adoption.
Bears Say
Financial Stability ConcernCompany's screening business expected to burn significant cash in 2024, posing a risk to financial stability.
Market Potential LimitationIf the confidence interval falls below the FIT benchmark, GH's product may only be approved for second line use, limiting its market potential.
Regulatory ChallengesLow Advanced Adenoma performance is likely to prompt a caution mention in the label, potentially increasing the recommended frequency of the test.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $41.06 in the past 12 months.
What is Guardant Health’s market cap?
Currently, no data Available
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Aug 01, 2024 which is in 72 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 09, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.068.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -$0.77.
How many shares outstanding does Guardant Health have?
Guardant Health has 122,369,220 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went up 15.072%.
Which hedge fund is a major shareholder of Guardant Health?
Among the largest hedge funds holding Guardant Health’s share is Deerfield Management Company, LP. It holds Guardant Health’s shares valued at 16M.
---
Guardant Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.33 (48.71% Upside)
$36.33 (48.71% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 66.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
-3883.89%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
---
GH Company Deck
---
GH Earnings Call
Q1 2024
0:00 / 0:00
---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$36.33
▲(48.71% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+15.98%
assigned a buy rating 9 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +15.98% per trade.
---